Compare Ross Stores, Inc. (ROST) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Ross Stores, Inc. trades at $252.25 (market cap $81.74B), while Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B). The key difference: Ross Stores, Inc. is far larger — about 45.9× Recursion Pharmaceuticals Inc's market cap, and Ross Stores, Inc. pays a 0.7% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ROST | RXRX | |
|---|---|---|
Market Cap | $81.74B | $1.78B |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $6.79 |
52-Week Low | $144.67 | $2.84 |
Enterprise Value | $82.34B | $1.30B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $255.23, up 0.36% on the day, near its consensus price target of $259. The stock shows strong momentum with a bullish technical signal and consistent earnings beats, including Q1 2026 EPS of $2.02 versus $1.73 expected. Revenue growth accelerated to $21.13B in 2025, with net income margin improving to 9.74%. Recent expansion includes 47 new stores opened in June-July 2026, supporting future growth.
Outlook remains positive given robust fundamentals and analyst optimism, but valuation multiples like P/E of 35.65 suggest premium pricing. Key risks include consumer spending sensitivity and competitive pressures in discount retail. The stock offers growth potential with disciplined execution, though investors should weigh high valuation against earnings sustainability.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
